The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
yes exactly. Clevergen is a new drug that takes advantage of the bodies own immune system by effectively waking the immune system up and increasing its effect on targeting cancer cells. The fact that this maybe has not worked on patients who have had previous invasive cancer treatments is because their immune system has been destroyed by those previous treatments.
What the study needs to focus on is new patients that have had no previous treatments but these may be far and few between.
Its the same with Traumakine whereas patient have had steroids as part of their treatment which again has an adverse effect on the drug and finding patients to study on is ever difficult because of standard treatments being used first. IMO
but followed with an explanation why:-
Faron is investigating why the observed immune activation has not turned into anti-tumour activity in all study subjects. In part, the Company believes the patient's immune system receiving Clevegen as a last line of therapy could have been adversely affected by the underlying therapies they have received prior to taking part in the MATINS study, as previous chemotherapies can inactivate bone marrow, preventing revitalization of the immune system. Majority of patients have received 5-7 different treatment lines prior entering the MATINS study.
The drug works but only on patients who have not had steroids. So be optimistic that they can formulate future treatment plans without the use of steroids and therefore result in a proven success.
The problem is further understood and the study can go forward.
A partner would understand this, so no change here, most shares are in sticky hands so hold and don't let the mms con you into selling. Partner news due Hold